QNRX vs. RMED, SIGY, NXGL, AVGR, MOTS, DYNT, INVO, STSS, PSTV, and NVIV
Should you be buying Quoin Pharmaceuticals stock or one of its competitors? The main competitors of Quoin Pharmaceuticals include Ra Medical Systems (RMED), Sigyn Therapeutics (SIGY), NEXGEL (NXGL), Avinger (AVGR), Motus GI (MOTS), Dynatronics (DYNT), INVO Bioscience (INVO), Sharps Technology (STSS), Plus Therapeutics (PSTV), and InVivo Therapeutics (NVIV). These companies are all part of the "surgical & medical instruments" industry.
Quoin Pharmaceuticals vs.
Ra Medical Systems (NYSE:RMED) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.
Ra Medical Systems has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.
Ra Medical Systems presently has a consensus price target of $12.00, suggesting a potential upside of 7,172.73%. Quoin Pharmaceuticals has a consensus price target of $50.00, suggesting a potential upside of 918.33%. Given Ra Medical Systems' higher possible upside, analysts plainly believe Ra Medical Systems is more favorable than Quoin Pharmaceuticals.
In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Ra Medical Systems. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 3 mentions for Ra Medical Systems. Quoin Pharmaceuticals' average media sentiment score of 1.28 beat Ra Medical Systems' score of -1.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.
Quoin Pharmaceuticals has lower revenue, but higher earnings than Ra Medical Systems.
2.8% of Ra Medical Systems shares are held by institutional investors. Comparatively, 21.7% of Quoin Pharmaceuticals shares are held by institutional investors. 1.0% of Ra Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Quoin Pharmaceuticals has a net margin of 0.00% compared to Ra Medical Systems' net margin of -110,533.34%. Quoin Pharmaceuticals' return on equity of 0.00% beat Ra Medical Systems' return on equity.
Ra Medical Systems received 85 more outperform votes than Quoin Pharmaceuticals when rated by MarketBeat users. However, 75.00% of users gave Quoin Pharmaceuticals an outperform vote while only 57.89% of users gave Ra Medical Systems an outperform vote.
Summary
Quoin Pharmaceuticals beats Ra Medical Systems on 9 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Quoin Pharmaceuticals Competitors List